Lv43
484 积分 2022-12-14 加入
CDK4/6 Inhibitor Resistance in ER+ Breast Cancer
27天前
已完结
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective
27天前
已完结
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
28天前
已完结
[Consensus on the clinical use of CDK4/6 inhibitors for the treatment of hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer (2023 edition)]
28天前
已完结
[Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2023 edition)]
1个月前
已完结
A First-in-Human, Phase 1, Multicenter, Open-label, Dose-Escalation Study of PCA062, an Antibody-Drug Conjugate Targeting P-Cadherin, in Patients with Solid Tumors
2个月前
已关闭
Characterization of the Human Full-Length PTK7 cDNA Encoding a Receptor Protein Tyrosine Kinase-Like Molecule Closely Related to Chick KLG
2个月前
已完结
Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation
4个月前
已完结
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
4个月前
已完结
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)
4个月前
已完结
皖公网安备34019202002308
